Aptamer Group to host technical development update webinar

Aptamer Group

Aptamer Group plc (LON:APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, has announced that Dr David Bunka, Chief Scientific Officer, will host a webinar to provide an update on the Company’s progress within its technical development programmes.

The webinar will be broadcast on Thursday, 14 August 2025, at 6:00 pm (BST) and will offer a detailed review of the latest data and technical developments, building on insights shared through recent regulatory announcements.

The webinar is open to shareholders and other interested parties who can register for the event by using the following link: https://www.turnerpope.com/register/

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer Group to host technical development update webinar

    Aptamer will hold a webinar on 14 August 2025 at 6:00 pm BST, led by Chief Scientific Officer Dr David Bunka, to present the latest data and progress across its technical development programmes.

    Aptamer Group reports 41% revenue growth and new licensing deals

    Aptamer Group posted unaudited revenue of £1.20 million for the year ended 30 June 2025, up 41% from the previous year. The company secured two new royalty agreements and advanced multiple licensing discussions, supported by a strengthened cash position following a £1.83 million fundraise.

    Aptamer Group extends Unilever collaboration for deodorant Optimers

    Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials.

    Aptamer Group raises £2.0 million in share placing

    Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will accelerate commercialisation of the Optimer® platform, support in-house manufacturing, launch new biomarker services and develop AI-driven aptamer discovery.

    Aptamer Group raises £2m to fund growth

    Aptamer Group plc has raised £2.0 million (before expenses) via a placing of new ordinary shares at 0.3p per share, representing a 21.1% discount.

    Aptamer advances liver fibrosis therapy with targeted gene delivery

    Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells.

      Search

      Search